Shattuck Labs to Present Phase 1 Data for SL-325, Marking Key De-Risking Milestone

What happened

Shattuck Labs announced it will host an investor call on June 8 to present comprehensive Phase 1 data for SL-325, a DR3-blocking antibody for inflammatory bowel disease. This marks a significant shift from the previous pre-IND status highlighted in the DeepValue report, where execution risk was high due to lack of human data. The Phase 1 data will cover safety, tolerability, PK, receptor occupancy, pharmacodynamics, and immunogenicity, providing the first clinical readout for this potential first-in-class asset. While the TL1A/DR3 axis has attracted substantial deal activity, data quality and differentiation versus ligand-targeting programs will determine the stock's trajectory. Despite this milestone, financing and Nasdaq listing compliance risks persist, given the company's reliance on external capital and a market cap around $90M.

Implication

If Phase 1 data show clean safety and class-competitive biomarkers, Shattuck could attract partnership interest and reduce financing overhang, but proof-of-concept in IBD remains distant, and the company still depends on future funding until a deal materializes.

Thesis delta

The key risk shifts from 'if the IND is accepted' to 'whether Phase 1 data are competitive.' Previously, the thesis required IND acceptance as a binary gate; now with data in hand, the focus moves to differentiation versus TL1A targeting programs. Clean data could unlock a SPECULATIVE BUY upgrade, while weak data would keep the stock on AVOID.